CEO statement
Our goal is to develop a disease modifying therapeutic vaccine for the treatment, and prevention of the progression, of Alzheimer’s disease. A long-acting and cost-efficient drug will make it possible for patients to lead an independent life without impact from the disease.
“The positive results in the phase 1b study further strengthen our confidence in that ALZ-101 can become a unique therapeutic vaccine”
– Kristina Torfgård, CEO, Alzinova
The future looks bright
We are proud of our research and are dedicated to deliver a therapeutic oligomer-specific vaccine against Alzheimer’s disease. It is a unique vaccine that makes the body generate its own antibodies that target only the toxic oligomers of amyloid-β (Aβ), which are believed to be the cause of Alzheimer’s disease — a disease that is one of the most common and devastating neurological diseases globally, today afflicting over 30 million people.
Alzinova’s lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer’s disease. The vaccine is in clinical development with a phase 1b study in Alzheimer’s patients. This marks the first study with ALZ-101 on humans, and is thus a so-called safety study, where the objective is to demonstrate safety and good tolerability of the therapeutic vaccine ALZ-101 in patients with early Alzheimer’s disease.
In the clinical study, we also examine the patients’ immune response, as well as a number of different exploratory biological markers that are associated with Alzheimer’s disease.
We shared top-line data in November 2023 from part A in the phase 1b study. The results showed that the study met the primary endpoint of safety and tolerability after 20 weeks. Further we noticed a high immune responder rate as well as antibody levels increasing with the number of doses given.
The results from the full analysis of part A confirm that ALZ-101 is a promising vaccine candidate against Alzheimer’s disease and strengthen our confidence in that ALZ-101 can become a unique therapeutic vaccine and thus help patients suffering from Alzheimer’s disease and their families to a better life.
It feels great to have come this far and to be able to contribute to the development of a vaccine that really has the potential to treat patients with this devastating disease.
We look forward to continuing the work with the extension of the phase 1b study, part B, as well as to evaluate the higher dose, which strategically was added to the study, to optimse the dose in preparations for the next clinical phase – a phase 2 study.
A unique and highly specific therapeutic vaccine
Immunotherapeutic drug candidates, binding to aggregated Aβ, is the only type of therapy that has shown positive effects in clinical trials. Our drug candidate ALZ-101 and the ALZ-201 antibody differ from previously tested candidates against Alzheimer’s disease, which bind non-specifically and to differing degrees to various forms of Aβ. Completed clinical trials on other candidates indicate that the specificity matters, to achieve efficacy as well as to avoid adverse side effects.
ALZ-101 is unique and a highly specific therapeutic vaccine, directed towards the toxic form of oligomeric Aβ. It has the opportunity to become an effective treatment to halt and prevent the progression of Alzheimer’s disease.
Learn more
Learn more about Alzheimer’s disease, our programs and the potential of our unique proprietary AβCC technology.
